AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02270294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai traditional massage
Description: Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
Study NCT02270294 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No massage
Description: The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
Study NCT00953056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.
Study NCT00953056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
Study NCT00953056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.
Study NCT00953056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
Study NCT01842217 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FES-PET
Study NCT01598506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Study NCT01415414 — intervention group
Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
Study NCT00483977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
Study NCT00483977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: oral for 2 weeks.
Study NCT00483977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-000592379
Description: PF-00592379: oral, 30 mg, once a day for 2 weeks
Study NCT03417154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
Study NCT03417154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Cyclophosphamide (CTX) Daily
Description: Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
Study NCT03417154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Cyclophosphamide (CTX) Every 7 Days
Description: Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
Study NCT02387502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation- Macintosh laryngoscope
Description: Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
Study NCT02387502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation- MacCoy laryngoscope
Description: In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
Study NCT02387502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation- Airtraq laryngoscope
Description: In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
Study NCT01885598 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT02864459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular ultrasound
Description: Muscular ultrasound is done before extubation
Study NCT02780752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hymecromone
Description: Oral Hymecromone
Study NCT00995800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate / Formoterol fumarate
Description: 2 dose strength vs. placebo
Study NCT00995800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate / Formoterol fumarate
Description: 2 dose strength vs. placebo
Study NCT02611583 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation
Study NCT02611583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation
Study NCT01956838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami
Description: intraduodenal infusion of umami tastant
Study NCT01956838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter
Description: intraduodenal infusion of bitter tastant
Study NCT01956838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet
Description: intraduodenal infusion of sweet tastant
Study NCT01684293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy-based cognitive rehabilitation
Description: Occupational therapy-based cognitive rehabilitation
Study NCT01684293 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation/games
Description: Psychoeducation/games
Study NCT01647347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supra- and subgingival rinsing with 10% PVP-iodine
Description: rinsing prior to and during subgingival ultrasonic debridement
Study NCT01647347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT00088764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training
Description: 8 sessions of pain and stress coping skills training
Study NCT00088764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Description: 4 sessions of writing about stress
Study NCT00088764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis education
Description: 8 sessions of learning about rheumatoid arthritis
Study NCT00088764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behavior writing
Description: 4 sessions of writing about various health behaviors
Study NCT02902861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
Study NCT02902861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( for Methotrexate)
Description: NaCl-Solution manufactured to mimic Methotrexate
Study NCT01563809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH+LH
Description: 75 IU of LH will be given from stimulation day 1
Study NCT02087696 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
Study NCT02284243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Study NCT02284243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Study NCT00976560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
Study NCT00976560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
Study NCT01227993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Study NCT00889720 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
Study NCT00175396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Androgen suppression, radiotherapy
Description: Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
Study NCT00175396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Androgen suppression, radiotherapy, iodine 125 brachytherapy
Description: Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
Study NCT00555516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EW02
Description: 1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.
Study NCT00555516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EW02
Description: 1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.
Study NCT01470118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcaftadine 0.25% ophthalmic solution
Description: One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Study NCT01470118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine 0.2% ophthalmic solution
Description: One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Study NCT01470118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Description: One drop of placebo instilled in each eye at Day 0 and Day 14.
Study NCT01339052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT01339052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT01009216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: Doses will be administered daily for 5 days.
Study NCT01663103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
Study NCT01663103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
Study NCT00235365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meta-cognitive therapy
Description: Meta-cognitive therapy
Study NCT00235365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waiting list
Description: waiting list control
Study NCT02124993 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
Study NCT00363480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone 50/250 mcg
Description: Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
Study NCT00363480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 mcg
Description: This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
Study NCT00363480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS™ powder inhalers
Description: Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
Study NCT04885777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution.
Study NCT04885777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution.
Study NCT00675610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication training
Description: providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
Study NCT01792752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced HIV Care Access and Retention Intervention
Description: Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
Study NCT01792752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing Campaign
Description: When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
Study NCT01792752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Re-engagement Campaign
Description: Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
Study NCT01792752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Linkage to Care and Substance Abuse Treatment Team
Description: The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
Study NCT01792752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Care Clinic
Description: Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
Study NCT03557060 — intervention group
Intervention type: DRUG
Intervention: Nucala
Description: NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
Study NCT02321176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trans-resveratrol
Description: patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient
Study NCT00523302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
Study NCT00523302 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
Study NCT04032093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: RSV vaccine
Study NCT04032093 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution for injection (0.9% sodium chloride injection)
Study NCT01004991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 on Day 8 of each of 6 cycles
Study NCT01004991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 on Day 8 of each of 6 cycles
Study NCT01004991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 on Day 8 of each of 6 cycles
Study NCT01004991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 on Day 8 of each of 6 cycles
Study NCT01004991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg PO days 8-12 of each of 6 cycles
Study NCT01004991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
Study NCT02149043 — intervention group
Intervention type: DEVICE
Intervention: Thermography
Description: Thermographic imaging of the patient's abdomen surface
Study NCT02149043 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Endoscopic examination of the colon
Study NCT02331888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp electrode, fetal doppler and EUM
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
Study NCT04563949 — intervention group
Intervention type: OTHER
Intervention: Repeat Testing
Description: Repeat Testing with the PLA will be conducted
Study NCT04691076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is administered by target-controlled infusion